Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:20 A.M. ET, MONDAY, OCTOBER 28, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at TCT 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22730?guestAccessKey=1ceacfdf-69b0-46ec-a184-624f63ed513b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102824

 

About The Study: In asymptomatic patients with severe aortic stenosis and myocardial fibrosis, early aortic valve intervention had no demonstrable effect on all-cause death or unplanned aortic stenosis–related hospitalization. The trial had a wide 95% CI around the primary end point, with further research needed to confirm these findings.

Corresponding Author: To contact the corresponding author, Marc R. Dweck, PhD, email marc.dweck@ed.ac.uk.

 

(doi:10.1001/jama.2024.22730)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Inhaled Reliever Therapies for Asthma

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 8 A.M. ET, MONDAY, OCTOBER 28, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American College of Allergy, Asthma & Immunology’s Annual Scientific Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22700?guestAccessKey=dd710369-e153-4cee-b56d-c9c93d5ecf22&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102824

 

About The Study: In this network meta-analysis of patients with asthma, inhaled corticosteroids combined with formoterol and inhaled corticosteroids combined with short-acting β agonists were each associated with reduced asthma exacerbations and improved asthma control compared with short-acting β agonists alone.

Corresponding Author: To contact the corresponding author, Derek K. Chu, MD, PhD, email chudk@mcmaster.ca.

 

(doi:10.1001/jama.2024.22700)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, OCTOBER 30, 2024

Media advisory: The full study and commentary are linked to this news release. This study is being presented at TCT 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4266?guestAccessKey=1ba6a510-a25d-4fe3-b356-948ff8eed4b5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103024

 

About The Study: In this cohort study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) had strong psychometric properties in patients with severe tricuspid regurgitation, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe tricuspid regurgitation as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as transcatheter tricuspid valve intervention, in rigorously controlled trials. 

Corresponding Author: To contact the corresponding author, Suzanne V. Arnold, MD, MHA, email sarnold@saint-lukes.org.

 

(doi:10.1001/jamacardio.2024.4266)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

BMI and Postacute Sequelae of SARS-CoV-2 Infection in Children and Young Adults

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, OCTOBER 28, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.41970?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study, elevated body mass index (BMI) was associated with a significantly increased post-acute sequelae of SARS-CoV-2 infection risk in a dose-dependent manner, highlighting the need for targeted care to prevent chronic conditions in at-risk children and young adults. 

Corresponding Author: To contact the corresponding author, Yong Chen, PhD, email ychen123@pennmedicine.upenn.edu.

 

(doi:10.1001/jamanetworkopen.2024.41970)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prenatal Cannabis Exposure and Executive Function and Aggressive Behavior at Age 5

Posted by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, OCTOBER 28, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.4352?guestAccessKey=684dd027-eaa8-48db-a2d7-fdf37ddcd5d4&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102824

 

About The Study: Results from this contemporary U.S. cohort where prenatal cannabis exposure was common and indicated that exposed children exhibited some differences in aspects of executive function and behavior relevant to long-term academic success and adaptive functioning. These results may be considered in refining clinical recommendations regarding cannabis use during pregnancy.

Corresponding Author: To contact the corresponding author, Sarah A. Keim, PhD, email sarah.keim@nationwidechildrens.org.

 

(doi:10.1001/jamapediatrics.2024.4352)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Cerebral Embolic Protection by Geographic Region

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 2:30 P.M. (ET), TUESDAY, OCTOBER 29, 2024

Media advisory: The full study is linked to this news release. This study is being presented at TCT 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4278?guestAccessKey=323860f8-c29c-4d58-ad6f-728382ca987a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102924

 

About The Study: The PROTECTED transcatheter aortic valve replacement (TAVR) trial could not show that the use of cerebral embolic protection (CEP) had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the U.S. cohort but not in the outside the U.S. cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics or procedural practices affect CEP efficacy. 

Corresponding Author: To contact the corresponding author, Raj R. Makkar, MD, email raj.makkar@cshs.org.

 

(doi:10.1001/jamacardio.2024.4278)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 1:30 P.M. ET, FRIDAY, OCTOBER 25, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Society of Nephrology Kidney Week 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22718?guestAccessKey=06a428c8-6891-42ae-82eb-4ee320a85943&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102524

 

About The Study: Among patients hospitalized with acute kidney injury, recommendations from a kidney action team did not significantly reduce the composite outcome of worsening acute kidney injury stage, dialysis, or mortality, despite a higher rate of recommendation implementation in the intervention group than in the usual care group.

Corresponding Author: To contact the corresponding author, F. Perry Wilson, MD, email francis.p.wilson@yale.edu.

 

(doi:10.1001/jama.2024.22718)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial Residential Segregation and Mental Health During Pregnancy

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.3669?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102524

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Hospitalization for COVID-19, Other Respiratory Infections, and Postacute Patient-Reported Symptoms

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, OCTOBER 25, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.41615?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cohort study found that postacute infection syndrome is not unique to COVID-19; it can also occur in people with other severe lower respiratory tract infections (LRTIs). However, compared with other LRTIs, COVID-19 appeared to impose an extra burden of neurological, cognitive, and fatigue symptoms. These findings highlight the similarities and differences between post–COVID-19 condition and postacute infection syndrome triggered by other pathogens, which will inform tailored clinical management and offer mechanistic insights into these previously overlooked syndromes. 

Corresponding Author: To contact the corresponding author, Junqing Xie, DPhil, email junqing.xie@ndorms.ox.ac.uk.

 

(doi:10.1001/jamanetworkopen.2024.41615)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, OCTOBER 25, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.41380?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cross-sectional study of privately insured patients found a more than 2-fold increase in use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications from 2022 to 2023, with a 25.6% decrease in the rate of metabolic bariatric surgery during the same period. Our results provide a national contemporaneous estimate of the decline in metabolic bariatric surgery associated with the era of GLP-1 RAs. 

Corresponding Author: To contact the corresponding author, Thomas C. Tsai, MD, MPH, email ttsai@bwh.harvard.edu.

 

(doi:10.1001/jamanetworkopen.2024.41380)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Social Media and Suicide Risk in Youth

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, OCTOBER 25, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.41499?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This overview identifies research gaps and methodological challenges that need to be addressed to guide intervention strategies and future policy relevant to youth and suicide risk. 

Corresponding Author: To contact the corresponding author, Lisa H. Jaycox, PhD, email lisa.jaycox@nimh.gov.

 

(doi:10.1001/jamanetworkopen.2024.41499)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Glomerular Filtration Rate Changes Following UTI in Children With Vesicoureteral Reflux

Posted by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 1 P.M. (ET), THURSDAY, OCTOBER 24, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Society of Nephrology Kidney Week 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.4546?guestAccessKey=2757062a-e5ee-4982-a9db-22eea6057289&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102424

 

About The Study: This cohort study uses data from the Children With Vesicoureteral Reflux trial to assess estimated glomerular filtration rate (eGFR) changes in participants with vs without recurrent urinary tract infections.

Corresponding Author: To contact the corresponding author, David S. Hains, MD, MBA, email dhains@iu.edu.

 

(doi:10.1001/jamapediatrics.2024.4546)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 24, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.19662?guestAccessKey=5344c8b7-0e87-4c88-9660-55b788317c15&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102424

 

About The Study: These interim findings demonstrate the feasibility of targeted interpretation of a predefined set of genes from genome sequencing in a population of different racial and ethnic groups. DNA sequencing offers an additional method to improve screening for conditions already included in newborn screening and to add those that cannot be readily screened because there is no biomarker currently detectable in dried blood spots. Additional studies are required to understand if these findings are generalizable to populations of different racial and ethnic groups and whether introduction of sequencing leads to changes in management and improved health outcomes.

 

Quote from corresponding author, Wendy K. Chung, MD, PhD:

“The GUARDIAN study represents a significant advancement in newborn health by demonstrating the feasibility of improving and expanding newborn screening to include hundreds of rare genetic disorders. This expansion enables earlier detection and treatment and promotes health equity.

“Notably, 72% of parents approached enrolled in the study. Among the 120 true positive results, 92% received a confirmed diagnosis for conditions not included in standard newborn screening, allowing for rapid, sometimes life-saving, treatment initiation and significantly reducing the time required for patients to receive a diagnosis.”

 

Contact information for Wendy K. Chung, MD, PhD: email Wendy.Chung@childrens.harvard.edu.

 

(doi:10.1001/jama.2024.19662)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Fentanyl, Heroin, Methamphetamine, and Cocaine Analyte Concentrations in Urine Drug Testing Specimens

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 24, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.41063?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cross-sectional study found that absolute concentrations of fentanyl, methamphetamine, and cocaine in urine specimens increased from 2013 to 2023, with a decrease in heroin concentration during that period. The findings suggest that exposure to these substances, as well as the illicit drug supply, has fundamentally changed in many parts of the U.S., highlighting the need to reinforce surveillance initiatives and accelerate efforts to treat individuals with illicitly manufactured fentanyl and/or stimulant exposure. 

Corresponding Author: To contact the corresponding author, Andrew S. Huhn, PhD, MBA, email ahuhn1@jhmi.edu.

 

(doi:10.1001/jamanetworkopen.2024.41063)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial Disparities in Receipt of Guideline-Concordant Care in Older Adults With Early Breast Cancer

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 24, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.41056?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study, non-Hispanic Black race was associated with increased odds of not receiving guideline-concordant care (GCC) and less timely treatment initiation. Non-Hispanic Black race was associated with increased all-cause mortality, which was reduced after adjusting for GCC and clinical and sociodemographic factors. These findings suggest that optimizing timely receipt of GCC may represent a modifiable pathway to improving inferior survival outcomes among older non-Hispanic Black patients with breast cancer.

Corresponding Author: To contact the corresponding author, Yehoda M. Martei, MD, MSCE, email yehoda.martei@pennmedicine.upenn.edu.

 

(doi:10.1001/jamanetworkopen.2024.41056)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Social Determinants of Health and US Health Care Expenditures by Insurer

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, OCTOBER 23, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.40467?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102324

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of 14,000 insured adults, individual-level social determinants of health were significantly associated with U.S. health care expenditures by Medicare, Medicaid, and private insurers. These findings may inform health insurers and policymakers to incorporate social determinants of health in their decision-making practices to identify and control health care expenditures, advancing health equity. 

Corresponding Author: To contact the corresponding author, Giridhar Mohan, MPH, email gmohan1@jhu.edu.

 

(doi:10.1001/jamanetworkopen.2024.40467)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Traumatic and Adverse Childhood Experiences and Developmental Differences in Psychiatric Risk

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, OCTOBER 23, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3231?guestAccessKey=f6802585-2f18-42ae-8ffd-df385e068fce&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102324

 

About The Study: In this cohort study, distinct forms of traumatic and adverse childhood experiences differentially moderated developmental changes in psychiatric risk and cognitive ability in different ways, offering the possibility for precision-based prediction of risk for youth. Such findings could be used in targeted early prevention and intervention strategies for at-risk youth. 

Corresponding Author: To contact the corresponding author, Justin D. Russell, PhD, email jdrussell3@wisc.edu

 

(10.1001/jamapsychiatry.2024.3231)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Perspectives on Medical School Admission for Black Students Among Premedical Advisers at Historically Black Colleges and Universities

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.40887?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102324

No Comments

Filed under:

GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, OCTOBER 23, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.18581?guestAccessKey=cd902433-0cd6-41d6-ab19-9ee8613ac394&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102324

 

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in a database increased between 2010 and 2023. Differences in characteristics of the overall T1D population and those newly prescribed the medications are often associated with elevated cardiorenal risk profiles, suggesting use of these newer treatments was intended to address additional medical needs. Concerns about euglycemic diabetic ketoacidosis led to the removal of SGLT2 inhibitors for T1D in Europe, and the U.S. Food and Drug Administration has not approved their use in T1D.

 

Quote from corresponding author Hui Shao, MD, PhD:

“Despite concerns that GLP-1 receptor agonists and SGLT2 inhibitors may cause serious adverse events such as ketoacidosis, the use of these medications in type 1 diabetes (T1D) has sharply increased over the past decade. This increase is likely to continue due to their significant benefits in weight management and cardiorenal protection observed in individuals with type 2 diabetes and the general obese population.

 

“Urgent studies are needed to evaluate the efficacy and safety of GLP-1RAs and SGLT2 inhibitors in the T1D population. Before such evidence becomes available, caution should be used when prescribing these treatments to individuals with T1D.”

 

Contact information for Hui Shao, MD, PhD: email hui.shao@emory.edu.)

 

(doi:10.1001/jama.2024.18581)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Maternal Eating Disorders, BMI, and Offspring Psychiatric Diagnoses

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, OCTOBER 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.40517?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this population-based cohort study including 392,000 mothers and 649,000 offspring, offspring from mothers with an eating disorder history or pre-pregnancy body mass index (BMI) outside normal weight were at higher risk of psychiatric disorders. The results differed somewhat between the 2 exposures with regard to which offspring diagnoses had associations, and effect sizes were typically larger for maternal eating disorders vs BMI. These findings suggest a need to consider these 2 exposures clinically to help prevent offspring mental illness.

Corresponding Author: To contact the corresponding author, Ida A. K. Nilsson, PhD, email ida.nilsson@ki.se.

 

(doi:10.1001/jamanetworkopen.2024.40517)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Toddler Screen Use Before Bed and Its Effect on Sleep and Attention

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.3997?guestAccessKey=c0c8379b-6753-40a8-8a13-ece32e4c400b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102124

No Comments

Filed under:

Levels of Satisfaction and Regret With Gender-Affirming Medical Care in Adolescence

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.4527?guestAccessKey=d1125010-920a-4d64-ba12-29f09d81af03&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102124

No Comments

Filed under:

World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 1 P.M. ET, SATURDAY, OCTOBER 19, 2024

Media advisory: The full article, editor’s note and related Viewpoints are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21972?guestAccessKey=1baf7916-9886-44d7-b376-aa02bc722147&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101924

 

About The Article: This article presents the 2024 revision of the World Medical Association’s Declaration of Helsinki, a set of principles to guide the ethical treatment of participants in medical research.

Corresponding Author: World Medical Association (wma@wma.net).

 

(doi:10.1001/jama.2024.21972)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Making the Ethical Oversight of All Clinical Trials Fit for Purpose

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 1 P.M. ET, SATURDAY, OCTOBER 19, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.0269?guestAccessKey=0e843b02-3531-4628-92b6-b4db8135bf69&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101924

 

About The Study: This article examines ethical oversight of clinical research in the U.S. and offers practical recommendations that are consistent with current regulations and that could help to make research oversight better fit for purpose for different types of studies.

Corresponding Author: To contact the corresponding author, Nancy E. Kass, ScD, email nkass@jhu.edu.

 

(doi:10.1001/jama.2024.0269)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

National Trends in Infant Mortality in the US After Dobbs

Posted by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, OCTOBER 21, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.4276?guestAccessKey=e7e9550e-5563-4801-bc4f-b743bed9ccff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102124

 

About The Study: Infant mortality was higher than expected, overall and among those with congenital anomalies, for several months after the Dobbs decision in the U.S. No post-Dobbs months (i.e., no months after June 2022) showed lower than expected infant mortality. These findings are consistent with the increase in infant mortality found in Texas following the state’s abortion ban.

Corresponding Author: To contact the corresponding author, Parvati Singh, PhD, email singh.1704@osu.edu.

 

(doi:10.1001/jamapediatrics.2024.4276)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Strategies to Help Patients Navigate High Prescription Drug Costs

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, OCTOBER 21, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.17275?guestAccessKey=62669f3e-7835-48ef-b478-eb0f7d258423&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102124

 

About The Study: The current patchwork of strategies to help patients manage high prescription drug costs highlights the structural and policy challenges within the U.S. prescription drug market that impede affordable access for some patients. While these strategies provide tangible solutions for clinicians to help patients access medically appropriate but costly medications, they do not address the root causes of high drug prices.

Corresponding Author: To contact the corresponding author, Hussain S. Lalani, MD, MPH, MSc, email hlalani@bwh.harvard.edu.

 

(doi:10.1001/jama.2024.17275)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, OCTOBER 18, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.39332?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

  

About The Study: In this randomized clinical trial of outpatients with mild to moderate COVID-19, treatment with montelukast did not reduce duration of COVID-19 symptoms. These findings do not support the use of montelukast for the treatment of mild to moderate COVID-19. 

Corresponding Author: To contact the corresponding author, Susanna Naggie, MD, MHS, email susanna.naggie@duke.edu.

 

(doi:10.1001/jamanetworkopen.2024.39332)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Accessibility of and Barriers to Long-Term Follow-Up Care for Childhood Cancer Survivors

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.40258?guestAccessKey=8ba4dd91-9b2e-48a7-b3b1-f83e660d8891&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101724

No Comments

Filed under:

Effect of Electric Fans on Body Core Temperature in Older Adults Exposed to Extreme Indoor Heat

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 17, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.19457?guestAccessKey=e631a5a0-d82e-47cb-ad6a-58a2cc3b260e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101724

 

About The Study: Electric fan use did not lower peak core temperature in older adults exposed to extreme indoor heat. Reductions in end-exposure core temperature and heart rate were observed, but they were small and of questionable clinical importance. Neither exceeded previous suggestions for clinical significance. Consistent with recent modeling, these data do not support fans as an efficacious standalone cooling intervention for older adults in hot indoor environments (>33-35 °C).

Corresponding Author: To contact the corresponding author, Glen P. Kenny, PhD, email gkenny@uottawa.ca.

 

(doi:10.1001/jama.2024.19457)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 17, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.16954?guestAccessKey=4b397f2f-45a2-45f1-8d13-9d0896a0c22f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101724

 

About The Study: Individuals receiving methadone had a lower risk of treatment discontinuation compared with those who received buprenorphine/naloxone. The risk of mortality while receiving treatment was similar between medications.

Corresponding Author: To contact the corresponding author, Bohdan Nosyk, PhD, email bnosyk@sfu.ca.

 

(doi:10.1001/jama.2024.16954)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prevalence of Glaucoma Among US Adults in 2022

Posted by Jim Michalski

JAMA Ophthalmology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, OCTOBER 17, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.3884?guestAccessKey=7c4ed689-a88b-4419-9d34-3ab4e26203d7&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101724

 

About The Study: This meta-analysis found that an estimated 2.56% of people 40 years or older have glaucoma, slightly more than estimated by previous studies. Black individuals are disproportionately affected. Prevalence estimates at the state and county level can help guide public health planning. 

Corresponding Author: To contact the corresponding author, Joshua R. Ehrlich, MD, MPH, email joshre@umich.edu.

 

(doi:10.1001/jamaophthalmol.2024.3884)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Comparison of Outcomes for Patients Treated by Allopathic vs Osteopathic Surgeons

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2024.4580?guestAccessKey=aae6c6d7-7046-4bb9-b8e2-11cad5290cf3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101624

No Comments

Filed under:

Testing and Evaluation of Health Care Applications of Large Language Models

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 1 P.M. ET, TUESDAY, OCTOBER 15, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21700?guestAccessKey=dcffc9b1-79d9-4409-9187-a60ea9c30a51&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101524

 

About The Study: Existing evaluations of large language models mostly focus on accuracy of question answering for medical examinations, without consideration of real patient care data. Dimensions such as fairness, bias, and toxicity and deployment considerations received limited attention. Future evaluations should adopt standardized applications and metrics, use clinical data, and broaden focus to include a wider range of tasks and specialties.

Corresponding Author: To contact the corresponding author, Nigam H. Shah, MBBS, PhD, email nigam@stanford.edu.

 

(doi:10.1001/jama.2024.21700)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

FDA Perspective on the Regulation of AI in Health Care and Biomedicine

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 1 P.M. ET, TUESDAY, OCTOBER 15, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21451?guestAccessKey=77fe8db1-4ed6-4fba-b753-54bc5343a047&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101524

 

About The Study: Strong oversight by the U.S. Food and Drug Administration (FDA) protects the long-term success of industries by focusing on evaluation to advance regulated technologies that improve health. The FDA will continue to play a central role in ensuring safe, effective, and trustworthy AI tools to improve the lives of patients and clinicians alike. However, all involved entities will need to attend to AI with the rigor this transformative technology merits.

Corresponding Author: To contact the corresponding author, Haider J. Warraich, MD, email haider.warraich@fda.hhs.gov.

 

(doi:10.1001/jama.2024.21451)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

In Utero Exposure to Maternal COVID-19 and Offspring Neurodevelopment Through Age 24 Months

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, OCTOBER 16, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.39792?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study of pregnant individuals and offspring, exposure to maternal COVID-19 was not associated with abnormal neurodevelopmental screening results through 24 months’ postpartum. Continued study of diverse groups of children is needed because, among other factors, evidence suggests sensitivity of the developing fetal brain to maternal immune activation. 

Corresponding Author: To contact the corresponding author, Eleni G. Jaswa, MD, MSc, MAS, email elenijaswa@gmail.com.

 

(doi:10.1001/jamanetworkopen.2024.39792)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

HLA-DRB1*01:03 and Severe Ulcerative Colitis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 4 A.M. ET, TUESDAY, OCTOBER 15, 2024

Media advisory: The full study is linked to this news release. This study is being presented at United European Gastroenterology Week 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20429?guestAccessKey=71e1d319-4c1e-494d-abaf-d17a65070d52&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101524

 

About The Study: Among individuals with ulcerative colitis, the allele HLA-DRB1*01:03 was associated with severe ulcerative colitis requiring major operation, hospitalization, and systemic corticosteroid use compared with less severe disease. HLA-DRB1*01:03 has previously been linked to ulcerative colitis incidence. This study supports earlier, targeted genetic studies comparing patients with healthy controls reporting an association with total disease and severe disease requiring colectomy.

Corresponding Author: To contact the corresponding author, Marie Vibeke Vestergaard, MSc, email marievv@dcm.aau.dk.

 

(doi:10.1001/jama.2024.20429)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, OCTOBER 16, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.18575?guestAccessKey=3a35c89f-2281-49c1-ae17-1885e3cffb8e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101624

 

About The Study: This Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49, compared with nonuse. LNG-IUS use constitutes the preferred hormonal contraception among Danish premenopausal women older than 30 years. Although the absolute breast cancer risk is low in young women, this study found an excess risk of 14 per 10,000 females. The risk did not increase with duration of use.

Corresponding Author: To contact the corresponding author, Lina Steinrud Mørch, MSc, PhD, email morch@cancer.dk.

 

(doi:10.1001/jama.2024.18575)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Hospital Strain During the COVID-19 Pandemic and Outcomes in Older Racial and Ethnic Minority Adults

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, OCTOBER 15, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.38563?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study, older adults hospitalized with sepsis were more likely to die or experience major morbidity as the hospital COVID-19 burden increased. These increases in adverse outcomes were greater in magnitude among members of minority populations than for white individuals. 

Corresponding Author: To contact the corresponding author, Laurent G. Glance, MD, email laurent_glance@urmc.rochester.edu.

 

(doi:10.1001/jamanetworkopen.2024.38563)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Acupuncture vs Sham Acupuncture for Chronic Sciatica From Herniated Disk

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.5463?guestAccessKey=6288cecb-4296-4e9c-8d42-8960ced5e0fd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424

No Comments

Filed under:

Free Summer Programming and BMI Among Schoolchildren From Low-Income Households

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.3693?guestAccessKey=14dbb50c-e63c-402b-9f2b-106864eaf00b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424

No Comments

Filed under:

Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 1 P.M. ET, MONDAY, OCTOBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21493?guestAccessKey=5a0d1022-a506-42cf-a93b-2546d78fea11&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424

 

About The Study: Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, with generic tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) being the most frequently prescribed medication since 2021. Injectable PrEP use was low likely because of barriers such as the high cost of stocking this expensive medication in clinics.

Corresponding Author: To contact the corresponding author, Laura M. Mann, PhD, MPH, email lmann@cdc.gov.

 

(doi:10.1001/jama.2024.21493)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 1 P.M. ET, MONDAY, OCTOBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21091?guestAccessKey=5165370f-513b-4ff6-bcc9-534bec6865ba&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424

 

About The Study: Mpox is a viral infection transmitted primarily through close skin to skin contact that typically causes a self-resolving illness but can result in severe illness and death in immunocompromised individuals. First-line therapy is supportive care, although patients with severe mpox infection may be treated with advanced therapeutics. Mpox vaccination is effective and, if available, should be offered to individuals at risk of exposure to mpox.

Corresponding Author: To contact the corresponding author, Jason Zucker, MD, MS, email Jz2700@cumc.columbia.edu.

 

(doi:10.1001/jama.2024.21091)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists

Posted by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, OCTOBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.3812?guestAccessKey=30dc2b89-6672-48bd-aba1-1936667825bf&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424

 

About The Study: In this study, adolescents with obesity prescribed a glucagon-like peptide 1 receptor agonists (GLP1R) had a lower incidence of suicidal ideation or attempts compared with matched patients not prescribed GLP1R who were treated with lifestyle intervention. These results suggest a favorable psychiatric safety profile of GLP1R in adolescents. The detected reduction in hazard ratios for suicidal ideation among adolescents with obesity prescribed GLP1R suggests potential avenues for future research.

Corresponding Author: To contact the corresponding author, Liya Kerem, MD, MSc, email liya.em@gmail.com.

 

(doi:10.1001/jamapediatrics.2024.3812)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

SARS-CoV-2 Infection and New-Onset Type 2 Diabetes Among Pediatric Patients

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, OCTOBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.39444?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this retrospective cohort study of children and adolescents ages 10 to 19, the risk of an incident diagnosis of type 2 diabetes was greater following a COVID-19 diagnosis than in children diagnosed with other respiratory infections. Further study is required to determine whether diabetes persists or reverses later in life. 

Corresponding Author: To contact the corresponding author, Pauline Terebuh, MD, MPH, email pdt@case.edu.

 

(doi:10.1001/jamanetworkopen.2024.39444)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Recovery From COVID-19–Related Disruptions in Cancer Detection

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, OCTOBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.39263?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cross-sectional study of nationally representative registry data found that cancer incidence recovered meaningfully in 2021 following substantial disruptions in 2020. However, incidence rates need to recover further to address the substantial number of patients with undiagnosed cancer during the pandemic. 

Corresponding Author: To contact the corresponding author, Uriel Kim, MD, PhD, MBA, email uxk13@case.edu.

 

(doi:10.1001/jamanetworkopen.2024.39263)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, OCTOBER 11, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.38918?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101124

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of the U.S. population during the COVID-19 public health emergency, excess mortality occurred in all racial and ethnic groups, with disparities affecting several minoritized populations. The greatest relative increases occurred in populations ages 25 to 64. Documented differences deviated from pre-pandemic disparities.

Corresponding Author: To contact the corresponding author, Jeremy Samuel Faust, MD, MS, email jsfaust@bwh.harvard.edu.

 

(doi:10.1001/jamanetworkopen.2024.38918)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Information About Sexual and Gender Minority Services and Policies on US Hospital Websites

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, OCTOBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.18345?guestAccessKey=18c5209b-c5f2-44f6-a5fa-ee85e97f9de1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424

 

About The Study: Most U.S. hospital websites explicitly included sexual and gender minority (SGM) populations in their nondiscrimination policies, but only a quarter of adult hospitals had an SGM-friendly clinician directory and provided information about SGM-related resources or hospital-based services. Pediatric hospitals more frequently posted SGM-related information than adult hospitals. Hospitals in states with more discriminatory policies were less likely to provide SGM-related information online.

Corresponding Author: To contact the corresponding author, Alex S. Keuroghlian, MD, MPH, email akeuroghlian@mgb.org.

 

(doi:10.1001/jama.2024.18345)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Electronic Nudges to Increase Influenza Vaccination in Patients With Chronic Diseases

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 12 P.M. ET, FRIDAY, OCTOBER 11, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21060?guestAccessKey=7925f7dc-e83b-43e8-ae76-bbe1e392949e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101124

 

About The Study: In a nationwide randomized clinical implementation trial, electronically delivered letter-based nudges markedly increased influenza vaccination compared with usual care among young and middle-aged patients with chronic diseases. The results of this study suggest that simple, scalable, and cost-efficient electronic letter strategies may have substantial public health implications.

Corresponding Author: To contact the corresponding author, Tor Biering-Sorensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com.

 

(doi:10.1001/jama.2024.21060)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Physician Altruism and Spending, Hospital Admissions, and Emergency Department Visits

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.3383?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101124

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.4412?guestAccessKey=d3ee1b75-af19-4aab-b0c3-70e1207647fd&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101024

No Comments

Filed under:

Racial and Ethnic Disparities in Receipt of Retinal Imaging Among Patients With Diabetes

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.4120?guestAccessKey=6c64f6e2-bbb4-4a3b-9129-5ce613403256&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101024

No Comments

Filed under:

Payments by Drug and Medical Device Manufacturers to US Peer Reviewers of Major Medical Journals

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 10, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.17681?guestAccessKey=4bbabdcb-70df-4352-883e-026fc020919b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101024

 

About The Study: More than half of the 1,962 U.S. physicians included in this study who peer reviewed for the most influential medical journals received industry payments in 2020-2022, with most payments for research. Research payments, especially those provided to an institution, may have different implications than general payments for conflicts of interest.

Corresponding Author: To contact the corresponding author, Christopher J. D. Wallis, MD, PhD, email wallis.cjd@gmail.com.

 

(doi:10.1001/jama.2024.17681)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Macronutrient and Micronutrient Intake Among US Women Ages 20 to 44

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 10, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.38460?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cross-sectional study of pregnant and nonpregnant women of reproductive age found that vitamin A, vitamin C, and iron intake decreased over the past 2 decades, which may have substantial maternal and fetal health implications. By identifying these nutrient gaps and trends in inadequate intake in this at-risk population, scientific, health care, and regulatory communities may be better poised to adopt recommendations to improve nutrient intake. 

Corresponding Author: To contact the corresponding author, Derek Miketinas, PhD, RD, email dmiketinas@twu.edu.

 

(doi:10.1001/jamanetworkopen.2024.38460)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 7:45 A.M. ET, WEDNESDAY, OCTOBER 9, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the European Society of Intensive Care Medicine LIVES 2024 Annual Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20424?guestAccessKey=5a01802a-53cf-4361-a113-0ad39b10fe93&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100924

 

About The Study: Patients with acute brain injury and anemia randomized to a liberal transfusion strategy were less likely to have an unfavorable neurological outcome than those randomized to a restrictive strategy.

Corresponding Author: To contact the corresponding author, Fabio Silvio Taccone, MD, PhD, email fabio.taccone@ulb.be.

 

(doi:10.1001/jama.2024.20424)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Effect of Tele-ICU on Clinical Outcomes of Critically Ill Patients

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 7:45 A.M. ET, WEDNESDAY, OCTOBER 9, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the European Society of Intensive Care Medicine LIVES 2024 Annual Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20651?guestAccessKey=623ab620-696c-473c-8107-f132f5261593&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100924

 

About The Study: Daily multidisciplinary rounds conducted by a board-certified intensivist through telemedicine did not reduce intensive care unit (ICU) length of stay in critically ill adult patients.

Corresponding Author: To contact the corresponding author, Adriano J. Pereira, M.D., Ph.D., email adrianojop@einstein.br.

 

(doi:10.1001/jama.2024.20651)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Extracorporeal Blood Purification and Acute Kidney Injury in Cardiac Surgery

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 7:45 A.M. ET, WEDNESDAY, OCTOBER 9, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the European Society of Intensive Care Medicine LIVES 2024 Annual Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20630?guestAccessKey=50555113-5c5e-42a9-88f8-481649673fa2&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100924

 

About The Study: The use of a nonselective extracorporeal blood purification device connected to the cardiopulmonary bypass circuit in a nonemergent population of patients undergoing cardiac surgery was associated with a significant reduction of cardiac surgery–associated acute kidney injury in the first 7 days after surgery.

Corresponding Author: To contact the corresponding author, Xose L. Perez-Fernandez, PhD, MD, email xose74@gmail.com.

 

(doi:10.1001/jama.2024.20630)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Frequency of Screening and Spontaneous Breathing Trial Techniques

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 7:45 A.M. ET, WEDNESDAY, OCTOBER 9, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the European Society of Intensive Care Medicine LIVES 2024 Annual Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20631?guestAccessKey=5fe24794-e804-43c8-b63b-f17d31d0b6f2&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100924

 

About The Study: Among critically ill adults who received invasive mechanical ventilation for more than 24 hours, screening frequency (once-daily vs more frequent screening) and spontaneous breathing trial (SBT) technique (pressure-supported vs T-piece SBT) did not change the time to successful extubation. However, an unexpected and statistically significant interaction was identified; protocolized more frequent screening combined with pressure-supported SBTs increased the time to first successful extubation.

Corresponding Author: To contact the corresponding author, Karen E. A. Burns, MD, MSc, email karen.burns@unityhealth.to.

 

(doi:10.1001/jama.2024.20631)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Suicidal Thoughts and Behaviors Among Autistic Transgender or Gender-Nonconforming US College Students

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, OCTOBER 9, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.38345?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=100924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cross-sectional study addresses the dearth of information on how intersectionality in gender and autism status impacts the risk of suicidal thoughts and behaviors, and the results confirm the elevated risk of suicidal thoughts and behaviors among transgender or gender nonconforming and autistic populations. Interventions are needed to support college students with these identities. 

Corresponding Author: To contact the corresponding author, Annabelle M. Mournet, MS, email amm883@psych.rutgers.edu.

 

(doi:10.1001/jamanetworkopen.2024.38345)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Incidence of Hospitalizations Involving Alcohol Withdrawal Syndrome

Posted by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, OCTOBER 8, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.38128?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=100824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study of a large primary care population served by an integrated health system, alcohol withdrawal syndrome (AWS) hospitalizations were common, especially in male patients, younger age groups, and individuals with high-risk alcohol use. During hospitalizations, the burden of AWS was similar to or exceeded complications of other chronic diseases that receive greater medical attention.

Corresponding author: To contact the corresponding author, Tessa L. Steel, M.D., M.P.H., email tessita@uw.edu.

 

(doi: 10.1001/jamanetworkopen.2024.38128)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under: